UPMC surgeons use surgical pen that draws lines on heart to treat atrial fibrillation

November 19, 2001

University of Pittsburgh one of first centers in U.S. trial

PITTSBURGH, - The University of Pittsburgh Medical Center (UPMC) is one of nine centers in the United States to evaluate an experimental surgical "pen" for the treatment of the most common cardiac rhythm disorder, atrial fibrillation. UPMC is the second center in the United States to perform surgery using the Medtronic Cardioblateä RF Surgical Ablation System, a device that allows surgeons to "draw" lines on the heart's upper chambers, essentially creating a maze that blocks the irregular rhythms. To date, UPMC surgeons have performed the surgery in three patients.

Atrial fibrillation (AF) is an abnormal heart rhythm originating in the right and left atria. Rapid and chaotic beats, independent of the ventricles, cause patients to experience palpitations, dizziness, fatigue, chest discomfort and/or shortness of breath. Such inefficient pumping in the atria can cause blood flow to be sluggish, increasing the likelihood that clots will form that result in stroke.

AF affects more than 5.5 million worldwide. Its prevalence increases with age -- almost 70 percent with AF are between 65 and 85 years of age. More than a third of those affected are considered to have "chronic" AF and have failed medical treatments that include drugs and cardioversion techniques designed to restore normal rhythm.

The Cardioblate pen was designed to simplify an otherwise complicated and tedious surgical procedure to treat AF. While highly effective, few surgeons perform the surgery, called the Maze, because of its complexity; the surgery involves making more than 34 incisions on the inside surface of the atria and suturing these incisions to create a "maze" that interrupts the pathways of erratic electrical impulses. Using the Cardioblate pen, which at its tip delivers a cool irrigation fluid and radiofrequency energy, surgeons can "draw" lines, creating deep lesions or scars, instead of making incisions.

"With this device we think we can achieve the same effect as with the traditional Maze procedure. And without the tedious cutting and sewing, the pen allows us to draw the same sort of pattern, but in less than 15 minutes. Importantly, as with the traditional Maze operation, the surgeon has access to the left atria, where most of the irregular impulses originate. Outpatient ablation techniques can only address problems in the right atrium," said Marco A. Zenati, M.D., assistant professor of surgery, division of cardiothoracic surgery, University of Pittsburgh School of Medicine, and principal investigator for the Pittsburgh study. Dr. Zenati is among only 10 or so surgeons in the United States trained to perform the modified Maze with the Cardioblate pen.

Currently, use of the device is limited to those who meet criteria for entry into the study as well as to those who require cardiac surgery to correct another heart problem besides AF.

Medtronic expects data of the U.S. study, as well as data collected in Europe, to lead to approval of the device by the U.S. Food and Drug Administration (FDA) early next year. Approval would mean the device would be indicated for patients with AF.

"FDA approval will allow us to treat patients with AF as their only heart problem. It will also allow us to further develop the procedure to be done minimally invasively as well as on a beating heart, without the use of a heart/lung machine," said Dr. Zenati, who is working with Medtronic to develop the next generation of technology.

"To be able to offer a surgical treatment for patients adds to our armamentarium of options for this complicated yet common cardiac problem, " said David Schwartzman, M.D., associate professor of medicine, Cardiovascular Institute, and director of the UPMC Health System's Atrial Arrhythmia Center. Dr. Zenati is the center's co-director.
UPMC's Atrial Arrhythmia Center is the only center in which a cardiologist and a cardiac surgeon work collaboratively to individualize and combine therapeutic strategies for all types of atrial arrhythmias, including AF. In addition, it is the only center in the region that uses radiofrequency catheter ablation, an outpatient procedure, to treat AF as well as the only one to implant a pacemaker-like device specifically designed to treat AF. UPMC has the world's largest experience implanting this device.

The Pittsburgh site includes both UPMC Presbyterian and the VA Pittsburgh Healthcare System in Oakland. For more information about the Pittsburgh site of the study, please call Anita Kalchthaler, R.N., 412-383-7253.

CONTACT: Lisa Rossi or Frank Raczkiewicz
PHONE: 412-647-3555
FAX: 412-624-3184
E-MAIL: RossiL@msx.upmc.edu

University of Pittsburgh Medical Center

Related Atrial Fibrillation Articles from Brightsurf:

Atrial fibrillation less deadly than it used to be, but still cause for concern: BU study
A first-of-its-kind study by researchers from the Boston University School of Public Health (BUSPH) shows a decline in deaths related to atrial fibrillation (irregular heartbeat) over the last 45 years.

Postoperative atrial fibrillation does not impact on overall survival after esophagectomy
Volume 11, Issue 25 of Oncotarget reported that Administration of landiolol hydrochloride was found to be associated with reduced incidence of atrial fibrillation after esophagectomy for esophageal cancer in our previous randomized controlled trial.

People with atrial fibrillation live longer with exercise
More than 100,000 Norwegians have atrial fibrillation. They should be actively exercising for their health.

Atrial fibrillation among overweight people is not due to fat
In a recently published study, researchers from Aarhus University document that the risk of atrial fibrillation is not linked to the amount of body fat, but instead to large muscle mass, or more precisely, a high fat-free weight

Eating more protein could help ward off atrial fibrillation in women
Women who ate slightly more than the recommended daily amount of protein were significantly less likely to develop atrial fibrillation (AFib), a dangerous heart rhythm disorder that can lead to stroke and heart failure, when compared with those who consumed less protein, according to research being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Zebrafish teach researchers more about atrial fibrillation
Genetic research in zebrafish at the University of Copenhagen has surprised the researchers behind the study.

Personalized medicine for atrial fibrillation
The study, published in Europace, uses signals from implantable devices -- pacemakers and defibrillators -- to analyze electrical signals in the heart during episodes of atrial fibrillation.

Prescribing anticoagulants in the ED for atrial fibrillation increases long-term use by 30%
Patients prescribed anticoagulants after a diagnosis of atrial fibrillation in the emergency department are more likely to continue long-term use of medications to treat the condition, according to research published in CMAJ (Canadian Medical Association Journal).

Anticoagulant benefits for atrial fibrillation decrease with age
The net clinical benefit of anticoagulants for atrial fibrillation (AF) -- one of the most important causes of irregular heartbeats and a leading cause of stroke -- decreases with age, as the risk of death from other factors diminishes their benefit in older patients, according to a study led by researchers at UC San Francisco.

Research improves understanding of mechanism of atrial fibrillation
Mouse model studies show that noncoding DNA regions linked to atrial fibrillation risk can display long-range regulatory functions directed at Pitx2 gene and in this way predispose to the condition.

Read More: Atrial Fibrillation News and Atrial Fibrillation Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.